48.45
6.25 (14.81%)
| Previous Close | 42.20 |
| Volume | 2,829,049 |
| Price / Earnings (Forward) | 10.55 |
| Price / Sales | 9.39 |
| Price / Book | 20.58 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,135.42% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | 5.00% |
| Total Debt/Equity (MRQ) | 297.04% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -99.23 M |
| Levered Free Cash Flow (TTM) | -64.38 M |
| Return on Assets (TTM) | -37.66% |
| Return on Equity (TTM) | -203.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Liquidia Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | 0.0 |
| Price Volatility | 2.2 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | -2.5 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.64 |
Select this tab to load the latest available analysis.
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 13.64% |
| % Held by Institutions | 65.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Findell Capital Management Llc | 30 Jun 2026 | 3,502,112 |
| Caprock Group, Llc | 30 Jun 2026 | 1,409,759 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ADAIR JASON | - | 43.74 | -688 | -30,093 |
| BOYLE DANA | - | 43.74 | -1,581 | -69,153 |
| Aggregate Net Quantity | -2,269 | |||
| Aggregate Net Value ($) | -99,246 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 43.74 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ADAIR JASON | Officer | 26 Oct 2026 | Automatic sell (-) | 688 | 43.74 | 30,093 |
| BOYLE DANA | Officer | 26 Oct 2026 | Automatic sell (-) | 1,581 | 43.74 | 69,153 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |